Last Price$93.51NASDAQ Previous Close - Last Trade as of 3:59PM ET 6/05/20

Today's Change-0.29(0.31%)
Bid (Size)$90.00 (4)
Ask (Size)$96.70 (20)
Day Low / High$90.17 - 96.32
Volume1.6 M

Incyte Plans to Submit New Drug Application for Eczema Cream Following Phase Three Testing

1:48PM ET 4/06/2020 MT Newswires
Shares of Incyte (INCY) said on Monday that data from a study of its cream for eczema -- Atopic Dermatitis -- supports a plan for the company to submit a new drug application before the end of 2020.

The company said Ruxolitinib resulted in a "rapid and robust" clinical response, meeting its primary endpoint such as clear skin based on data from phase three study. The secondary endpoint -- the proportion of patients who achieved a 75% improvement in the eczema area -- was also met.

The overall safety profile was consistent with previous study data, with no new safety signals observed.

Price: 83.66, Change: +5.07, Percent Change: +6.45